



OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.

Visit [go.covermymeds.com/OptumRx](http://go.covermymeds.com/OptumRx) to begin using this free service.

Please note: All information below is required to process this request.

Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

## Promacta® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)			Provider Information (required)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:		Specialty:
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:
Medication Information (required)					
Medication Name:			Strength:		Dosage Form:
<input type="checkbox"/> Check if requesting <b>brand</b>			Directions for Use:		
<input type="checkbox"/> Check if request is for <b>continuation of therapy</b>					
Clinical Information (required)					
<b>Select the diagnosis below:</b>					
<input type="checkbox"/> Chronic hepatitis C-associated thrombocytopenia					
<input type="checkbox"/> Chronic idiopathic thrombocytopenic purpura (ITP)					
<input type="checkbox"/> Severe aplastic anemia					
<input type="checkbox"/> Other diagnosis: _____ ICD-10 Code(s): _____					
<b>Prescriber's Specialty:</b>					
Select if Promacta is prescribed by or in consultation with one of the following specialists:					
<input type="checkbox"/> Gastroenterologist		<input type="checkbox"/> HIV specialist certified through the American Academy of HIV Medicine			
<input type="checkbox"/> Hematologist/oncologist		<input type="checkbox"/> Infectious disease specialist			
<input type="checkbox"/> Hepatologist					
<b>For chronic idiopathic thrombocytopenic purpura (ITP), answer the following:</b>					
Select the patient's diagnosis:					
<input type="checkbox"/> Chronic immune (idiopathic) thrombocytopenic purpura (ITP)					
<input type="checkbox"/> Relapsed/refractory ITP					
Is the patient's baseline platelet count less than 30,000/microliter? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Select if the patient has had trial and failure, contraindication, or intolerance to the following:					
<input type="checkbox"/> Corticosteroids		<input type="checkbox"/> Immunoglobulins		<input type="checkbox"/> Splenectomy	
Does the patient's degree of thrombocytopenia and clinical condition increase the risk of bleeding? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Reauthorization:</b>					
Is there documentation the patient has had a positive clinical response to Promacta therapy as evidenced by an increase in platelet count to a level sufficient to avoid clinical important bleeding? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>For chronic hepatitis C-associated thrombocytopenia, answer the following:</b>					
Does the patient have a diagnosis of chronic hepatitis C-associated thrombocytopenia? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient planning to initiate and maintain interferon-based treatment? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Is the patient currently receiving interferon-based therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
<b>Reauthorization:</b>					
Is the patient currently receiving interferon-based therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No					
For patients that started treatment with Promacta prior to initiation of treatment with interferon, is there documentation the patient has reached a threshold platelet count that allows initiation of antiviral interferon therapy with Promacta treatment by week 9? <input type="checkbox"/> Yes <input type="checkbox"/> No					

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of OptumRx. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**

Office use only: Promacta\_Comm\_2019Mar-W



## Promacta<sup>®</sup> Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

**For severe aplastic anemia, answer the following:**

Has the patient had trial and failure, contraindication, or intolerance to immunosuppressive therapy with antithymocyte globulin (ATG) and cyclosporine?  Yes  No

Does the patient have thrombocytopenia, defined as a platelet count less than 30,000/microliter?  Yes  No

**Reauthorization:**

Is there documentation the patient has had a positive clinical response to Promacta therapy as evidenced by an increase in platelet count?  Yes  No

**Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?**

---

---

Please note:

This request may be denied unless all required information is received.

For urgent or expedited requests please call 1-800-711-4555.

This form may be used for non-urgent requests and faxed to 1-800-527-0531.